Navigation Links
CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
Date:9/17/2007

Hernia repair is one of the most commonly performed surgical procedures

worldwide

ATLANTA, Ga., Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed a distribution agreement allowing Proxy Biomedical Limited to include CryoLife's BioGlue(R) Surgical Adhesive into a hernia repair kit. In addition to BioGlue, the kit includes a surgical mesh from Proxy Biomedical's line of proprietary synthetic polymer surgical meshes. Initially, Proxy Biomedical will distribute the kits in Ireland, the United Kingdom and Germany.

"Hernia repair is one of the most commonly performed surgical procedures worldwide. BioGlue is already approved for this particular indication in international markets, and we believe that BioGlue, coupled with Proxy Biomedical's proprietary meshes, will give surgeons a unique option for the repair of hernia and other fascial defects," stated Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

"We believe that BioGlue provides a highly competitive method for atraumatic surgical mesh fixation. BioGlue has been used effectively for several surgical procedures, and we look forward to providing the product in kit form with our series of next generation surgical mesh products. BioGlue offers a simple and effective solution for surgical mesh fixation with enhanced procedural value," stated Peter Gingras, managing director of Proxy Biomedical Limited.

Currently, the most common methods of hernia mesh fixation include sutures and tacking systems. Between 10 and 20 percent of patients complain of pain resulting from hernia repair, most often associated with the fixation method. It is anticipated that the use of BioGlue, as an adjunct to sutures and tacking systems, will help minimize this incidence of postoperative pain.

BioGlue is distributed directly by CryoLife Europa in the UK and Germany for all types of soft tissue repair, including in cardiac, neuro and general surgery. In Ireland, the product is distributed through a distributor for the same indications.

About BioGlue

BioGlue is a two-component adhesive that creates a flexible, mechanical seal, independent of the body's clotting mechanism, within 20 to 30 seconds, and reaches its maximum bonding strength in two to three minutes.

It is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels, and is CE-marked in the European Community. In addition, BioGlue is approved in Canada for use in soft tissue repair and in Australia for use in vascular and pulmonary sealing and repair.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. In addition to BioGlue, the Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community. For additional information about CryoLife please visit http://www.cryolife.com.

About Proxy Biomedical Limited

Founded in 2002, Proxy Biomedical Limited, located in Galway, Ireland, is a privately held, life science company engaged in commercializing proprietary biomaterials for the repair and regeneration of tissue. Proxy Biomedical's proprietary surgical mesh products include MotifMesh, VitaMesh, MotifMesh MIDS, and VitaMesh MIDS, which are CE marked for distribution within the European Community and FDA approved for distribution within the United States.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated benefits of using BioGlue in Proxy Biomedical's hernia repair kits. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioGlue may not help minimize post- operative pain to the extent anticipated or may otherwise prove ineffective in hernia repair, and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2006, its most recent Form 10-Q, and the Company's other SEC filings. The Company does not undertake to update its forward- looking statements.

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Fleishman Hillard

Chief Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. JT Packard exec resigns after settling copyright disputes
2. Cray signs $250M deal to develop supercomputer
3. Donley resigns as WiCell director
4. WARF signs licensing pact with BD Biosciences
5. TeraMedica signs agreement with ThedaCare
6. CATI signs agreement for food processing technology
7. Doyle signs bill that impacts electronic medical records
8. Doyle signs "self-dealing" bill
9. Electronic signs for municipalities: Las Vegas or lost revenues?
10. NorthStar signs exclusive agreement with Illinois foundation
11. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  Market Research Future published a half-cooked research report on Global ... at a CAGR of 12% during the period 2016 to 2022. ... ... cell division without any control. These abnormal cells have the ability ... cells can spread to other parts of the body through the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... for Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine ... and isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ ...
(Date:1/17/2017)... 17, 2017  An international team of researchers ... St. Boniface Hospital Albrechtsen Research Centre/University of Manitoba ... unmet health need affecting nearly one in 15 ... Investigation, their results identify small molecule drugs with ... neuronal injury in animal models of metabolic, chemical ...
(Date:1/17/2017)... Ind. , Jan. 17, 2017  Zimmer Biomet ... fourth quarter and full-year 2016 sales and earnings conference ... Tuesday, January 31, 2017, at 8 a.m. Eastern Time.  ... will be made available at 7:30 a.m. Eastern Time ... live audio webcast can be accessed via Zimmer Biomet,s ...
Breaking Biology Technology:
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):